Browse PRRX1

Summary
SymbolPRRX1
Namepaired related homeobox 1
Aliases PHOX1; PMX1; paired mesoderm homeo box 1; AGOTC; PRX-1; homeobox protein PHOX1; paired mesoderm homeobox 1 i ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus.
Domain PF00046 Homeobox domain
PF03826 OAR domain
Function

Acts as a transcriptional regulator of muscle creatine kinase (MCK) and so has a role in the establishment of diverse mesodermal muscle types. The protein binds to an A/T-rich element in the muscle creatine enhancer (By similarity).

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001709 cell fate determination
GO:0002053 positive regulation of mesenchymal cell proliferation
GO:0007224 smoothened signaling pathway
GO:0007423 sensory organ development
GO:0008589 regulation of smoothened signaling pathway
GO:0010463 mesenchymal cell proliferation
GO:0010464 regulation of mesenchymal cell proliferation
GO:0010975 regulation of neuron projection development
GO:0019827 stem cell population maintenance
GO:0030326 embryonic limb morphogenesis
GO:0031099 regeneration
GO:0031102 neuron projection regeneration
GO:0035107 appendage morphogenesis
GO:0035108 limb morphogenesis
GO:0035113 embryonic appendage morphogenesis
GO:0042471 ear morphogenesis
GO:0042472 inner ear morphogenesis
GO:0042474 middle ear morphogenesis
GO:0043583 ear development
GO:0045165 cell fate commitment
GO:0045880 positive regulation of smoothened signaling pathway
GO:0048514 blood vessel morphogenesis
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048663 neuron fate commitment
GO:0048664 neuron fate determination
GO:0048701 embryonic cranial skeleton morphogenesis
GO:0048704 embryonic skeletal system morphogenesis
GO:0048705 skeletal system morphogenesis
GO:0048706 embryonic skeletal system development
GO:0048736 appendage development
GO:0048839 inner ear development
GO:0048844 artery morphogenesis
GO:0051216 cartilage development
GO:0060021 palate development
GO:0060173 limb development
GO:0060840 artery development
GO:0061448 connective tissue development
GO:0070570 regulation of neuron projection regeneration
GO:0090596 sensory organ morphogenesis
GO:0097150 neuronal stem cell population maintenance
GO:0098727 maintenance of cell number
GO:1904888 cranial skeletal system development
Molecular Function GO:0001076 transcription factor activity, RNA polymerase II transcription factor binding
GO:0001104 RNA polymerase II transcription cofactor activity
GO:0001105 RNA polymerase II transcription coactivator activity
GO:0001190 transcriptional activator activity, RNA polymerase II transcription factor binding
GO:0001191 transcriptional repressor activity, RNA polymerase II transcription factor binding
GO:0003713 transcription coactivator activity
GO:0071837 HMG box domain binding
GO:0098811 transcriptional repressor activity, RNA polymerase II activating transcription factor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolPRRX1
Namepaired related homeobox 1
Aliases PHOX1; PMX1; paired mesoderm homeo box 1; AGOTC; PRX-1; homeobox protein PHOX1; paired mesoderm homeobox 1 i ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PRRX1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPRRX1
Namepaired related homeobox 1
Aliases PHOX1; PMX1; paired mesoderm homeo box 1; AGOTC; PRX-1; homeobox protein PHOX1; paired mesoderm homeobox 1 i ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PRRX1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPRRX1
Namepaired related homeobox 1
Aliases PHOX1; PMX1; paired mesoderm homeo box 1; AGOTC; PRX-1; homeobox protein PHOX1; paired mesoderm homeobox 1 i ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PRRX1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.9050.00637
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.6020.474
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-2.1170.174
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.2720.0248
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0190.534
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.5820.483
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3350.622
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.6220.393
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.1330.578
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9820.546
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.2180.3
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3240.221
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PRRX1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPRRX1
Namepaired related homeobox 1
Aliases PHOX1; PMX1; paired mesoderm homeo box 1; AGOTC; PRX-1; homeobox protein PHOX1; paired mesoderm homeobox 1 i ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PRRX1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPRRX1
Namepaired related homeobox 1
Aliases PHOX1; PMX1; paired mesoderm homeo box 1; AGOTC; PRX-1; homeobox protein PHOX1; paired mesoderm homeobox 1 i ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PRRX1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PRRX1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPRRX1
Namepaired related homeobox 1
Aliases PHOX1; PMX1; paired mesoderm homeo box 1; AGOTC; PRX-1; homeobox protein PHOX1; paired mesoderm homeobox 1 i ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PRRX1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPRRX1
Namepaired related homeobox 1
Aliases PHOX1; PMX1; paired mesoderm homeo box 1; AGOTC; PRX-1; homeobox protein PHOX1; paired mesoderm homeobox 1 i ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PRRX1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPRRX1
Namepaired related homeobox 1
Aliases PHOX1; PMX1; paired mesoderm homeo box 1; AGOTC; PRX-1; homeobox protein PHOX1; paired mesoderm homeobox 1 i ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PRRX1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPRRX1
Namepaired related homeobox 1
Aliases PHOX1; PMX1; paired mesoderm homeo box 1; AGOTC; PRX-1; homeobox protein PHOX1; paired mesoderm homeobox 1 i ......
Chromosomal Location1q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PRRX1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.